Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after ...

Fintel reports that on May 14, 2025, Morgan Stanley downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...

On Tuesday, Leerink Partners issued a downgrade for Halozyme Therapeutics (NASDAQ:HALO) stock, changing its rating from Market Perform to Underperform. The firm also reduced its price target to $ ...

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting tumor ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (BMV:HALO) from Market Perform to Underperform. There are 607 funds or institutions ...

On Tuesday, Leerink Partners issued a downgrade for Halozyme Therapeutics (NASDAQ:HALO) stock, changing its rating from Market Perform to Underperform. The firm also reduced its price target to $47.00 ...